Endoscopy 2017; 49(10): 934-935
DOI: 10.1055/s-0043-118590
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Endoscopic resection in esophageal adenocarcinoma: a basic requirement for future management algorithms

Referring to Gotink AW et al. p. 941–948Neil Gupta1, Prateek Sharma2
  • 1Department of Gastroenterology, Loyola University Medical Center, Maywood, Illinois USA
  • 2Department of Gastroenterology, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, USA
Further Information

Publication History

Publication Date:
27 September 2017 (online)

Esophageal adenocarcinomas that are clinically staged as T2N0M0 remain a management dilemma for cancer care teams around the world. Patients with cT2N0M0 disease probably represent a heterogeneous group of true pathologic disease states including: (i) correctly staged “true” T2N0M0 disease; (ii) under-staged locally advanced disease (i. e. those with pathologic N1, T3, or aggressive grade tumors); and (iii) over-staged T1N0M0 disease. The challenge is deciphering into which group each individual patient with cT2N0M0 disease falls so that they can receive the appropriate initial therapy (endoscopic resection vs. surgical resection vs. neo-adjuvant chemoradiotherapy).

“…there is going to be a continued need for better methods to determine the best initial treatment method for patients with cT2N0M0 esophageal adenocarcinoma.”